Gam-COVID-Vac
An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04436471/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Совмещённое исследование фаз Фаза I–II: Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного. Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- В исследовании участвуют здоровые добровольцы.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–60 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 38 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (08.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 15 · невключение: 20
Критерии включения
- males and females within the age range from 18 to 60 years;
- written informed consent;
- subject body mass index (BMI): 18.5 ≤ BMI ≤ 30;
- negative PCR test results for SARS-CoV-2 (during the screening);
- no history of COVID-2019 disease;
- no contacts of volunteers with patients with COVID-2019 for at least 14 days;
- negative test results for IgM and IgG antibodies to SARS-CoV-2;
- subject agrees to use effective contraceptive methods during the entire period of participation in the study;
- absence of acute infectious diseases at the time of vaccine administration and 14 days before vaccination;
- negative pregnancy test of blood or urine (for women of childbearing age);
- subject has negative tests for HIV, hepatitis B and С, syphilis or confirmed medical history;
- subject has a negative result of the urine test for residual narcotic drugs;
- negative test for alcohol in exhaled air;
- the absence of malignant diseases of any nature and localization;
- in medical history and based on the screening results, subject has no diseases or pathologies of the gastrointestinal system, liver, kidneys, cardiovascular system and blood, CNS, musculoskeletal system, urogenital, immune and endocrine systems that from the point of view of the researcher and/or of the organizer of the study, may affect the safety of the volunteer and the evaluation of the study results (clinical, instrumental and laboratory tests did not reveal diseases or clinically significant deviations).
Критерии невключения
- volunteer involvement in another study over the last 90 days;
- any vaccination over the last 30 days;
- history of COVID-2019 disease;
- positive PCR test results for SARS-CoV-2 (during the screening);
- positive test results for IgM and IgG antibodies to SARS-CoV-2;
- health staff in contact with people with COVID-2019;
- respiratory symptoms in the last 14 days;
- the administration of immunoglobulins or other blood products in the last 3 months;
- regular current or past use of narcotic drugs;
- subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study;
- pregnancy or breast feeding;
- exacerbation of allergic diseases at the time of vaccination;
- subject has systolic blood pressure less than 100 mm Hg or greater than 139 mm Hg; diastolic blood pressure less than 60 mm Hg or greater than 90 mm Hg; heart rate lower than 60 beats per minute or above 100 beats per minute;
- a burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.);
- a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship;
- subject smokes more than 10 cigarettes per day;
- alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug;
- planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug;
- the presence of an associated disease that may affect the assessment of the results of the study;
- any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.
Источник: ClinicalTrials.gov, NCT04436471 · запись обновлена в реестре 12 августа 2020.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 2
- Changing ofantibody levels against the SARS-CoV-2 glycoprotein S in 42 days — at days 0,14, 21, 28, 42
- Number of Participants With Adverse Events — through the whole study, an average of 180 days
Цель исследования
The purpose of the study is to assess safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac ", a solution for intramuscular administration, with the participation of healthy volunteers
Study objectives A safety and tolerability assessment of the drug "Gam-COVID-Vac ", solution for intramuscular administration, using single dose of each component (Stage 1).
A safety and tolerability assessment of the drug "Gam-COVID-Vac ", solution for intramuscular administration, using prime-boost immunization according to the proposed scheme (Stage 2).
Post-vaccination immunity assessment at different time points after vaccination by:
* Determination of antigen-specific antibody titer in blood serum by ELISA by comparison with baseline values before the vaccine administration and at days 14, 21, 28, and 42 after vaccination (hereinafter, the countdown comes from the first time of the vaccine administration);
* Determination of virus neutralizing antibody titer before and at days 14, 28, and 42 after vaccination;
* Determination of antigen-specific cellular immunity (specific T-cell immunity) before the vaccine administration and at days 14 and 28 after vaccination.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04436471 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.